The Pishesha Lab focuses on unraveling the biological complexities of antigen processing and presentation, particularly in the context of modulation of the immune response. We work extensively with nanobodies—single-chain proteins derived from camelid heavy chain-only immunoglobulins that retain their antibody-like specificity. They are simple to manufacture and modify, which explains their versatility.
At the Pishesha Lab, we perform our own alpaca immunization and screening campaigns to identify new nanobodies with desirable biological functions. Through protein engineering, we derivatize nanobodies to create therapeutic agents and immune modulators. We use them as innovative tools for biochemistry and immune imaging. Specifically, we explore the use of nanobody-based approaches to enhance specific immune responses. This is done by targeting the timing and route of administration of nanobodies, suitably modified for delivery of inflammatory signals to immune cells. The goal is to create a more effective immune response, not only in a vaccine setting, but also to overcome the suboptimal immune environment that is characteristic of various cancers. We test these strategies in preclinical mouse models and -where possible- in patient-derived samples. As an immunological counterpoint, we also explore nanobodies and their modifications as immune modulators to treat autoimmune diseases.
To learn more about us and our work, please visit us at pisheshalab.com.
